Michael R Megna sold $383k of KNSA
CHIEF ACCOUNTING OFFICER at Kiniksa Pharmaceuticals International, plc. 11,000 shares at an average of $34.84, traded Sep 3, 2025, filed Sep 3, 2025.
Score components
- +15RoleOfficer
- +16Trade size$383k at market
- +5Share of holdings soldSold 22% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-023564, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 1, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +2,363 | - | - | 35,404 | Sep 3, 2025 |
| Sep 1, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +2,557 | - | - | 37,961 | Sep 3, 2025 |
| Sep 1, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +3,933 | - | - | 41,894 | Sep 3, 2025 |
| Sep 1, 2025 | FTax withholding Class A Ordinary Share10b5-1 | -4,282 | $33.49 | $143k | 37,612 | Sep 3, 2025 |
| Sep 2, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +774 | - | - | 38,386 | Sep 3, 2025 |
| Sep 2, 2025 | FTax withholding Class A Ordinary Share10b5-1 | -375 | $34.28 | $13k | 38,011 | Sep 3, 2025 |
| Sep 3, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +11,000 | $17.92 | $197k | 49,011 | Sep 3, 2025 |
| Sep 3, 2025 | SOpen-market sale Class A Ordinary Share10b5-1 | -11,000 | $34.84 | $383k | 38,011 | Sep 3, 2025 |
| Sep 1, 2025 | AGrant or award Restricted Share Unitderivative10b5-1 | +10,575 | $0.00 | $0 | 10,575 | Sep 3, 2025 |
| Sep 1, 2025 | AGrant or award Share Optionderivative10b5-1 | +21,150 | $0.00 | $0 | 21,150 | Sep 3, 2025 |
| Sep 1, 2025 | MOption exercise Restricted Share Unitderivative10b5-1 | -2,363 | $0.00 | $0 | 7,087 | Sep 3, 2025 |
| Sep 1, 2025 | MOption exercise Restricted Share Unitderivative10b5-1 | -2,557 | $0.00 | $0 | 5,115 | Sep 3, 2025 |
| Sep 1, 2025 | MOption exercise Restricted Share Unitderivative10b5-1 | -3,933 | $0.00 | $0 | 3,932 | Sep 3, 2025 |
| Sep 2, 2025 | MOption exercise Restricted Share Unitderivative10b5-1 | -774 | $0.00 | $0 | 0 | Sep 3, 2025 |
| Sep 3, 2025 | MOption exercise Share Optionderivative10b5-1 | -11,000 | $0.00 | $0 | 0 | Sep 3, 2025 |
Related signals
Other insiders at Kiniksa Pharmaceuticals International, plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Kiniksa Pharmaceuticals International, plc | Michael R Megna CHIEF ACCOUNTING OFFICER | $369k 4,600 shares | -14% | |
| 40Moderate | Kiniksa Pharmaceuticals International, plc | Mark Ragosa CHIEF FINANCIAL OFFICER | $1.7M 36,722 shares | -75% | |
| 23Weak | Kiniksa Pharmaceuticals International, plc | John F. Paolini CHIEF MEDICAL OFFICER | $1.8M 40,000 shares | -39% | |
| 4Weak | Kiniksa Pharmaceuticals International, plc | Barry D Quart director | $126k 2,800 shares | -22% | |
| 37Weak | Kiniksa Pharmaceuticals International, plc | Mark Ragosa CHIEF FINANCIAL OFFICER | $772k 17,845 shares | -60% | |
| 29Weak | Kiniksa Pharmaceuticals International, plc | Barry D Quart director | $722k 15,960 shares | -119% | |
| 30Weak | Kiniksa Pharmaceuticals International, plc | Mark Ragosa CHIEF FINANCIAL OFFICER | $503k 12,000 shares | -39% | |
| 38Weak | Kiniksa Pharmaceuticals International, plc | Barry D Quart director | $836k 20,129 shares | -62% | |
| 28Weak | Kiniksa Pharmaceuticals International, plc | Eben Tessari CHIEF OPERATING OFFICER | $501k 12,048 shares | -42% | |
| 47Moderate | Kiniksa Pharmaceuticals International, plc | Mark Ragosa CHIEF FINANCIAL OFFICER | $1.8M 42,841 shares | -58% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.